Decreasing symptoms in interstitial cystitis patients: pentosan polysulfate vs. sacral neuromodulation

SOAR Home
→
Graduate School
→
GRASP: Graduate Research and Scholarly Projects
→
Proceedings: 3rd Annual Symposium: Graduate Research and Scholarly Projects
→
View Item

dc.contributor.author	Price, Katy D.
dc.contributor.author	Griffin, Audrey
dc.date.accessioned	2007-09-06T17:29:52Z
dc.date.available	2007-09-06T17:29:52Z
dc.date.issued	2007-04-27
dc.identifier.citation	Price, Katy D. & Griffin, Audrey.(2007).Decreasing symptoms in interstitial cystitis patients: pentosan polysulfate vs. sacral neuromodulation.In Proceedings : 3rd Annual Symposium : Graduate Research and Scholarly Projects. Wichita, KS : Wichita State University, p.108-109	en
dc.identifier.uri	http://hdl.handle.net/10057/858
dc.description	Paper presented to the 3rd Annual Symposium on Graduate Research and Scholarly Projects (GRASP) held at the Hughes Metropolitan Complex, Wichita State University, April 27, 2007.	en
dc.description	Research completed at Department of Physician Assistant, College of Health Professions ,Wichita state university.	en
dc.description.abstract	Oral pentosan polysulfate is the only FDA-approved drug for interstitial cystitis. Several studies have been conducted that show PPS will reduce IC symptoms. Sacral neuromodulation is a newer therapy for IC that has been FDAapproved in incontinent patients. Both therapies have studies documenting a reduction in IC symptoms, but no studies have compared these therapies to see which is more effective. Methods: An evidence-based systematic literature review was conducted using Pubmed, Medline, and Proquest nursing journals. Inclusion criteria were a peer-reviewed article, publish date of 1990 or later, level 1 or 2 evidence, were diagnosed with IC, and were only treated with either oral PPS or sacral neuromodulation during the study. Exclusion criteria were multiple therapies for IC or a non-IC diagnosis. Results: Three PPS studies fit all inclusion criteria. With successful treatment being defined as a 50% overall improvement in symptoms, studies had a success rate of 26-32%. Four studies fit the criteria for sacral neuormodulation. In these studies 40-94% of the patients had a 50% improvement in one or more IC symptom. Conclusions: PPS and sacral neuromodulation have both been shown to reduce IC symptoms. Sacral neuromodualtion has been shown to have a higher rate of symptom relief in IC patients. Based on level 2 evidence, a Grade B recommendation can be made for sacral neuromodulation. This evidence was limited by sacral neuromodulation studies having only level 2 evidence, while PPS has level 1 evidence studies. More studies are needed for each of these therapies.	en
dc.format.extent	154111 bytes
dc.format.mimetype	application/pdf
dc.language.iso	en_US	en
dc.publisher	Wichita State University. Graduate School.	en
dc.relation.ispartofseries	GRASP	en
dc.relation.ispartofseries	v.3	en
dc.title	Decreasing symptoms in interstitial cystitis patients: pentosan polysulfate vs. sacral neuromodulation	en
dc.type	Conference paper	en